Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cellâs nucleus with SINE technology (Selective Inhibition of Nuclear Export). Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies. Source
No articles found.
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...
Otsuka Holdings Co Ltd is a pharmaceutical comp...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...
AVEO Pharmaceuticals, Inc. is a biopharmaceutic...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.